Disease Severity in Vaccinated Adults Hospitalized with Breakthrough COVID-19

Hosp Top. 2024 Oct-Dec;102(4):223-230. doi: 10.1080/00185868.2022.2118093. Epub 2022 Sep 10.

Abstract

Background: Vaccination against SARS-CoV-2 is widely used and confers protection against morbidity and mortality in COVID-19. Little is known about disease severity and outcomes in fully vaccinated patients during hospitalization for COVID-19. Aim: To determine whether vaccination status and time from vaccination-to-hospitalization impacted disease severity in patients admitted with COVID-19. Methods: A multicenter retrospective cohort study was conducted on hospitalized adults with COVID-19 between January 1 and September 8, 2021, in Rhode Island, USA. Vaccination status and markers of disease severity, including C-reactive protein, D-Dimer values, and supplemental oxygen use during hospitalization, were obtained. Results: Two thousand three hundred forty-four patients were included. For every vaccinated patient, three unvaccinated patients were matched for a total of 424 patients in the analytic sample. Vaccinated patients had lower peak C-reactive protein (beta = -39.10, 95% CI [-79.10, -0. 65]) and supplemental oxygen requirements (beta = -38.14, 95% CI [-61.62, -9.91]) compared to unvaccinated patients. Patients who had a greater discrepancy between date of vaccination and admission had higher C-reactive protein (beta = 0.37, 95% CI [0.02, 0.71]) and supplemental oxygen requirements (beta = 0.44, 95% CI [0.15, 0.75]. Conclusion: Vaccination against SARS-CoV-2 was associated with a protective effect on disease severity during hospitalization for breakthrough COVID-19. Time elapsed since vaccination was associated with indicators of greater disease severity suggestive of waning protection over time.

Keywords: COVID-19; COVID-19 hospitalization; SARS-CoV-2 vaccination; breakthrough hospitalization; breakthrough infection; mRNA vaccination.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Breakthrough Infections
  • C-Reactive Protein / analysis
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / therapeutic use
  • COVID-19* / prevention & control
  • Cohort Studies
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Rhode Island
  • SARS-CoV-2
  • Severity of Illness Index*
  • Vaccination / statistics & numerical data

Substances

  • COVID-19 Vaccines
  • C-Reactive Protein

Supplementary concepts

  • COVID-19 breakthrough infections